English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: This study aimed to understand the infectivity period after symptom relief in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients using real-time reverse transcription polymerase chain reaction (RT-PCR). This would probably help prevent the disease spread by partially recovered patients to some extent. Methods: A total of 10 coronavirus disease 2019 (COVID-19) infected patients with mild to moderate illness, approved by RT-PCR, were followed daily. After 2 days of cessation of clinical symptoms, a nasopharyngeal and oropharyngeal sample RT-PCR was taken. If the patients’ test had a negative result, a repeated RT-PCR was performed 24 hours later. Moreover, if two consecutive tests had negative results, the patient was considered definitively treated, and the follow-up was terminated. However, if RT-PCR was positive, the test was performed 3 days later. The infectivity period after symptom relief and total infectivity period were calculated. The SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies were measured 1 month after symptom relief. The SPSS Software (version 20) was used for data analysis. Results: A total of 10 patients met the inclusion criteria to enter the study. There were 6 (60%) male and 4 (40%) female patients. The mean age of patients was 37.40 ± 7.975 years (minimum: 28 years, maximum: 51 years). The mean days passed from the onset of symptoms at the time of referring to Kowsar Hospital in Semnan, Iran, was 3.2 ± 0.919 days (minimum: 2 days, maximum: 5 days). The mean infectivity period after symptom relief was 6.9 ± 5.152 days indicating that it took about 7 days after symptom relief that the patients were considered completely treated according to RT-PCR results. However, the mean period of total infectivity was 16.6 ± 5.73 days. Moreover, 70% of patients had an IgM negative/IgG positive result 1 month after symptom relief; nevertheless, 30% of patients showed a delayed antibody response. Conclusions: The virus could be detected in nasopharyngeal and oropharyngeal samples in the studied patients up to 7 days after symptom relief. This finding highlights the importance of isolation and distancing in patients after recovery and the adoption of hygiene measures.

Infectivity Period After Symptom Relief in SARS-CoV-2 Patients: An Experimental Trial